Octreotide (Short-Acting)

Trade name

Octreotide (GH), Sandostatin

Presentation and preparation:

50 microgram/mL (volume: 1 mL)

100 microgram/mL (volume: 1 mL)

500 microgram/mL (volume: 1 mL)

IV administration

Octreotide short-acting formulation only.

Remove from refrigerator, allow to come to room temperature before injecting.

RCH: Refer to local protocol.

Dilute to 5 to 20 microgram/mL and give as an intermittent infusion over 15 to 30 minutes or give as a continuous infusion.

Maximum concentration if necessary: 40 microgram/mL.

May be given undiluted over 3 minutes in an emergency situation.

RCH Standard Concentrations:

NICU:

0 to < 1 kg: 125 microgram/25 mL (5 microgram/mL)

1 to < 3 kg: 250 microgram/25 mL (10 microgram/mL)

3 kg+: 500 microgram/25 mL (20 microgram/mL)

Other:

0 to < 3 kg: 500 microgram/50 mL (10 microgram/mL)

3 kg+: 1000 microgram/50 mL (20 microgram/mL)

Fluid restricted: 2000 microgram/50 mL (40 microgram/mL)

Other routes of administration

IM: Not recommended. 

SC: Octreotide short-acting formulation only. Suitable. Give undiluted using the concentration with smallest volume to reduce injection site pain.

May be given as a continuous subcutaneous infusion in palliative care settings.

Compatible IV fluids

Sodium chloride 0.9% is the preferred diluent.

Glucose 5%

Additional information

Do not confuse short-acting products with the octreotide long-acting depot preparations. Refer to Product Information for details.

Taper the infusion slowly when discontinuing treatment; abrupt discontinuation may cause rebound diarrhoea, biliary colic and pancreatitis.

Refrigerate, do not freeze.

Discard any unused vial contents.

Protect from light during storage.